Dynavax Technologies Corp (NASDAQ:DVAX)

CAPS Rating: 2 out of 5

A biopharmaceutical company that discovers and develops Toll-like Receptor 9 and agonist-based products to treat and prevent infectious diseases, allergies, cancer and chronic inflammatory.

Recs

0
Player Avatar SamsaricSufferer (< 20) Submitted: 11/17/2012 12:08:52 PM : Outperform Start Price: $2.50 DVAX Score: -75.16

Bounce play on a fundamentally sound company.

Featured Broker Partners


Advertisement